EDITORIAL: No time to waste in drawing up rules for genomic medicine

EDITORIAL: No time to waste in drawing up rules for genomic medicine

Publication date: Apr 13, 2019

Japan is on the cusp of a new era of cancer care as the medical community focuses more on impressive advances in genomic medicine, the science of customizing medical care to an individual’s unique genetic makeup.

Applied to cancer care, genomic medicine, also known as personalized medicine, involves tailoring treatment options to specific genetic abnormalities in individual patients that may be responsible for the spread of the disease.

While the use of this method will be limited to cases that meet certain criteria, mostly patients in advanced stages of cancer for whom standard cancer therapies no longer work, being able to use the public health care insurance program will create affordable new treatment options for many late-stage cancer patients.

Genomic information about individuals can be used for a wide range of areas in medical care, including diagnosis, treatment, risk assessment and prevention with regard to various diseases.

Precision medicine, also known as individualized medicine, also raises thorny issues, including the question of how much information about unexpectedly discovered gene mutations linked to specific cancer should be provided to the patients or their family members.

Genomic medicine also raises some broader issues, such as discrimination and other unfair treatment based on genetic information.

Concepts Keywords
Cancer Biotechnology
Comb Emerging technologies
Counseling Medical tests
Cusp Genomics
Discrimination Personalized medicine
Genetic Precision medicine
Genetic Diseases Cancer
Genetic Testing Genetic testing
Genomic Medicine Clinical medicine
Insurance Medical genetics
Japan Medicine
Medicine Branches of biology
Personalized Medicine Counseling
Precision Medicine Insurance policies
Revolutionary Strict management
Risk Assessment Public care insurance
Survey

Semantics

Type Source Name
gene UNIPROT ESR1
gene UNIPROT ERAL1
disease MESH cancer
disease DOID cancer
disease MESH community
disease MESH abnormalities
disease MESH diagnosis
disease MESH genetic diseases
disease MESH development

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *